1. Home
  2. VTMX vs IBRX Comparison

VTMX vs IBRX Comparison

Compare VTMX & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VTMX
  • IBRX
  • Stock Information
  • Founded
  • VTMX 1998
  • IBRX 2014
  • Country
  • VTMX Mexico
  • IBRX United States
  • Employees
  • VTMX N/A
  • IBRX N/A
  • Industry
  • VTMX
  • IBRX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • VTMX
  • IBRX Health Care
  • Exchange
  • VTMX Nasdaq
  • IBRX Nasdaq
  • Market Cap
  • VTMX 2.2B
  • IBRX 2.4B
  • IPO Year
  • VTMX 2023
  • IBRX N/A
  • Fundamental
  • Price
  • VTMX $26.21
  • IBRX $2.60
  • Analyst Decision
  • VTMX Buy
  • IBRX Buy
  • Analyst Count
  • VTMX 2
  • IBRX 2
  • Target Price
  • VTMX $33.50
  • IBRX $17.38
  • AVG Volume (30 Days)
  • VTMX 168.5K
  • IBRX 6.1M
  • Earning Date
  • VTMX 02-12-2025
  • IBRX 11-12-2024
  • Dividend Yield
  • VTMX 2.76%
  • IBRX N/A
  • EPS Growth
  • VTMX 2.33
  • IBRX N/A
  • EPS
  • VTMX 0.39
  • IBRX N/A
  • Revenue
  • VTMX $243,239,612.00
  • IBRX $7,332,000.00
  • Revenue This Year
  • VTMX N/A
  • IBRX $2,515.60
  • Revenue Next Year
  • VTMX $21.87
  • IBRX $766.19
  • P/E Ratio
  • VTMX $6.36
  • IBRX N/A
  • Revenue Growth
  • VTMX 18.11
  • IBRX 1218.71
  • 52 Week Low
  • VTMX $23.32
  • IBRX $2.50
  • 52 Week High
  • VTMX $41.44
  • IBRX $10.53
  • Technical
  • Relative Strength Index (RSI)
  • VTMX 57.08
  • IBRX 28.18
  • Support Level
  • VTMX $25.13
  • IBRX $2.50
  • Resistance Level
  • VTMX $26.23
  • IBRX $2.75
  • Average True Range (ATR)
  • VTMX 0.69
  • IBRX 0.25
  • MACD
  • VTMX 0.15
  • IBRX -0.11
  • Stochastic Oscillator
  • VTMX 76.26
  • IBRX 2.67

About VTMX Corporacion Inmobiliaria Vesta S.A.B de C.V. each representing ten (10)

Corporacion Inmobiliaria Vesta SAB de CV is a real estate company dedicated to the development and leasing of industrial buildings and distribution centers in Mexico. The Company's primary business is the acquisition, development, and management of industrial and distribution center real estate. The company designs and constructs park-to-suit projects across various industries; undertakes build-to-suit projects; and provides site selection, design and engineering, and sale and leaseback services. The primary source of revenues is the rental income received from customers under operating leases. It serves aerospace, automotive, food and beverage, logistics, medical devices, plastics, and other industries.

About IBRX ImmunityBio Inc.

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.

Share on Social Networks: